DE1692039A1 - Neue Verwendungsarten des Alkaloids Raubasin sowie entsprechende Zubereitungen - Google Patents

Neue Verwendungsarten des Alkaloids Raubasin sowie entsprechende Zubereitungen

Info

Publication number: DE1692039A1
Authority: DE; Germany
Prior art keywords: raubasin; treatment; alkaloid; venous; pressure
Prior art date: 1967-02-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

DE19681692039

Other languages

German (de)

English (en)

Inventor

Karl Dr Med Dietmann

Wolfgang Prof Dr Med Schaumann

Guenter Dr Med Steinorth

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Roche Diagnostics GmbH

Original Assignee

Boehringer Mannheim GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1967-02-10

Filing date

1968-01-26

Publication date

1971-07-08

1968-01-26 Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH

1971-07-08 Publication of DE1692039A1 publication Critical patent/DE1692039A1/de

Status Pending legal-status Critical Current

Links

ZLQMRLSBXKQKMG-UHFFFAOYSA-N rauniticine Natural products COC(=O)C1=CC2CC3N(CCc4c3[nH]c5ccccc45)CC2C(C)O1 ZLQMRLSBXKQKMG-UHFFFAOYSA-N 0.000 title claims description 47
GRTOGORTSDXSFK-UHFFFAOYSA-N ajmalicine Chemical compound C1=CC=C2C(CCN3CC4C(C)OC=C(C4CC33)C(=O)OC)=C3NC2=C1 GRTOGORTSDXSFK-UHFFFAOYSA-N 0.000 title claims description 45
229930013930 alkaloid Natural products 0.000 title claims description 9
150000003797 alkaloid derivatives Chemical class 0.000 title claims description 9
238000002360 preparation method Methods 0.000 title claims description 8
230000002093 peripheral effect Effects 0.000 claims description 17
230000000747 cardiac effect Effects 0.000 claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
238000002347 injection Methods 0.000 claims description 12
239000007924 injection Substances 0.000 claims description 12
208000035475 disorder Diseases 0.000 claims description 11
238000011282 treatment Methods 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 8
206010030113 Oedema Diseases 0.000 claims description 7
229940079593 drug Drugs 0.000 claims description 6
208000005230 Leg Ulcer Diseases 0.000 claims description 4
208000025865 Ulcer Diseases 0.000 claims description 4
238000011321 prophylaxis Methods 0.000 claims description 4
239000007787 solid Substances 0.000 claims description 4
231100000397 ulcer Toxicity 0.000 claims description 4
208000037997 venous disease Diseases 0.000 claims description 4
208000009447 Cardiac Edema Diseases 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 4
239000000825 pharmaceutical preparation Substances 0.000 claims 4
208000007536 Thrombosis Diseases 0.000 claims 2
241000282472 Canis lupus familiaris Species 0.000 description 12
230000004872 arterial blood pressure Effects 0.000 description 8
230000036772 blood pressure Effects 0.000 description 8
230000000694 effects Effects 0.000 description 8
239000008280 blood Substances 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
230000017531 blood circulation Effects 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
230000002792 vascular Effects 0.000 description 6
210000003462 vein Anatomy 0.000 description 6
210000000709 aorta Anatomy 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
230000001133 acceleration Effects 0.000 description 4
238000010253 intravenous injection Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
229940124549 vasodilator Drugs 0.000 description 4
239000003071 vasodilator agent Substances 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
206010040943 Skin Ulcer Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
206010046996 Varicose vein Diseases 0.000 description 3
230000036770 blood supply Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
208000027744 congestion Diseases 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
210000005245 right atrium Anatomy 0.000 description 3
208000027185 varicose disease Diseases 0.000 description 3
230000024883 vasodilation Effects 0.000 description 3
229920001817 Agar Polymers 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241000206672 Gelidium Species 0.000 description 2
CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
239000000654 additive Substances 0.000 description 2
235000010419 agar Nutrition 0.000 description 2
GRTOGORTSDXSFK-XJTZBENFSA-N ajmalicine Chemical compound C1=CC=C2C(CCN3C[C@@H]4[C@H](C)OC=C([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 GRTOGORTSDXSFK-XJTZBENFSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229920006158 high molecular weight polymer Polymers 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000203 mixture Substances 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
230000036513 peripheral conductance Effects 0.000 description 2
230000036581 peripheral resistance Effects 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000007395 thrombosis prophylaxis Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
CRBHXDCYXIISFC-UHFFFAOYSA-N 2-(Trimethylammonio)ethanolate Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
PEYPCTZOXFDFFW-UHFFFAOYSA-N 3-Iso-19-epi-ajnalicin Natural products C1=CC=C2C3CCN4CC5C(C)OC=C(C(=O)OC)C5CC4C3NC2=C1 PEYPCTZOXFDFFW-UHFFFAOYSA-N 0.000 description 1
BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
206010014513 Embolism arterial Diseases 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
206010017076 Fracture Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010020852 Hypertonia Diseases 0.000 description 1
208000032912 Local swelling Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
240000000233 Melia azedarach Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
-1 Stearic acid) Chemical class 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
210000002565 arteriole Anatomy 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
230000001517 counterregulatory effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
229960001484 edetic acid Drugs 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003999 initiator Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
210000000264 venule Anatomy 0.000 description 1
230000002618 waking effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229960000317 yohimbine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)

DE19681692039 1967-02-10 1968-01-26 Neue Verwendungsarten des Alkaloids Raubasin sowie entsprechende Zubereitungen Pending DE1692039A1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB6396/67A GB1115417A (en)	1967-02-10	1967-02-10	Compositions containing raubasine and a new method of using raubasine

Publications (1)

Publication Number	Publication Date
DE1692039A1 true DE1692039A1 (de)	1971-07-08

Family

ID=9813753

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE19681692039 Pending DE1692039A1 (de)	1967-02-10	1968-01-26	Neue Verwendungsarten des Alkaloids Raubasin sowie entsprechende Zubereitungen

Country Status (6)

Country	Link
US (1)	US3564094A (zh)
BE (1)	BE710562A (zh)
DE (1)	DE1692039A1 (zh)
FR (1)	FR7342M (zh)
GB (1)	GB1115417A (zh)
NL (1)	NL142593B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2092608B1 (zh) *	1970-06-01	1973-08-10	Roussel Uclaf
FR2671727B1 (fr) *	1991-01-18	1994-04-29	Nawrocki Thadee	Utilisation de la raubasine pour traiter un mauvais metabolisme de fer.

1967
- 1967-02-10 GB GB6396/67A patent/GB1115417A/en not_active Expired
1968
- 1968-01-26 DE DE19681692039 patent/DE1692039A1/de active Pending
- 1968-01-26 US US700875*A patent/US3564094A/en not_active Expired - Lifetime
- 1968-02-09 FR FR139329A patent/FR7342M/fr not_active Expired
- 1968-02-09 NL NL686801841A patent/NL142593B/xx unknown
- 1968-02-09 BE BE710562D patent/BE710562A/xx unknown

Also Published As

Publication number	Publication date
GB1115417A (en)	1968-05-29
US3564094A (en)	1971-02-16
NL142593B (nl)	1974-07-15
NL6801841A (zh)	1968-08-12
FR7342M (zh)	1969-10-13
BE710562A (zh)	1968-08-09

Publication	Publication Date	Title
DE68907909T2 (de)	1993-12-23	Präparat zur behandlung von erektionsstörungen.
EP0257344B1 (de)	1991-01-16	Arzneimittel enthaltend Dipyridamol oder Mopidamol und O-Acetylsalicylsäure bzw. deren physiologisch verträgliche Salze, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung der Thrombusbildung
DE69432905T2 (de)	2004-05-27	Verwendung von ketoconazol und verwandten substanzen in medikamenten für die behandlung des typ ii-diabetes
DE3119460A1 (de)	1982-03-04	Pharmazeutische zusammensetzung aus l-karnitin und/oder l-acylkarnitin und verwendung der zusammensetzung gegen diabetes mellitus bei jugendlichen
DE3317692A1 (de)	1983-11-24	Verwendung von metkephamid oder eines pharmazeutisch unbedenklichen salzes hiervon als analgetikum bei traechtigen weiblichen tieren und insbesondere bei schwangeren frauen
DE3850778T2 (de)	1994-10-27	Verwendung von tetracycline zur herstellung eines arzneimittels zum herabsetzen des augendrucks.
EP0363671B1 (de)	1994-01-26	Verwendung von ACE-Inhibitoren gegen Neointimabildung nach Gefässverletzung
DE69002946T2 (de)	1994-03-24	Paracetamol enthaltende arzneizubereitung.
DE3643119A1 (de)	1988-06-23	Therapeutische zusammensetzung fuer diabetes-komplikationen
Cunningham et al.	1981	The effect of intravenous diazepam on rise of intraocular pressure following succinylcholine
DE3234537C2 (de)	1986-01-02	Verwendung von 3-(2,2,2-Trimethylhydrazinium)propionatdihydrat zur Behandlung kardiovaskulärer Erkrankungen
DE3586993T3 (de)	1998-03-19	Kontinuierliche intravenöse infusion von adenosin an menschlichen patienten, einheitsdosierungsform von adenosin und dessen verwendung bei der herstellung von arzneimitteln.
DE1692039A1 (de)	1971-07-08	Neue Verwendungsarten des Alkaloids Raubasin sowie entsprechende Zubereitungen
EP0132595B1 (de)	1989-06-14	Tokolytisches Mittel
Malini et al.	1982	Renal haemodynamics after chronic treatment with labetalol and propranolol.
Green	1973	Permeability properties of the ciliary epithelium in response to prostaglandins
EP0324745B1 (de)	1995-01-11	Prostacyclinderivate enthaltende mittel für die topische anwendung
Quillen et al.	1977	Effects of arginine vasopressin on capillary filtration in the cat ileum
Innemee et al.	1978	An increase in intraocular pressure due to clonidine
DE60004996T2 (de)	2004-07-22	Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
Kondo	1971	Experimental studies on the relationship between the elevated venous pressure and osmolal arterio-venous difference
DE69118847T2 (de)	1996-09-05	Verwendung von Heptastigmin zur Behandlung der zerebralen Ictus
DE2055930A1 (de)	1972-05-18	Verbesserte orale Applikationsform von Raubasin
DE1926011A1 (de)	1971-02-11	Pharmazeutisches Praeparat mit antagonistischer Wirkung
DE2345291A1 (de)	1974-03-28	Therapeutisches mittel